Martingale Asset Management L P Has $17.08 Million Holdings in Becton, Dickinson and Company $BDX

Key Points

• Martingale Asset Management L P significantly increased its stake in Becton, Dickinson and Company by 105.5%, now holding 74,575 shares valued at approximately $17.1 million.
• A number of institutional investors have recently modified their holdings, including a notable 98.2% increase by Brighton Jones LLC and a 50.6% increase by Wealth Enhancement Advisory Services LLC.
• Analysts have mixed views on Becton, Dickinson and Company, with four analysts rating it as a "Buy" and seven as a "Hold", along with a consensus price target of $211.44.

Martingale Asset Management L P raised its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 105.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 74,575 shares of the medical instruments supplier's stock after buying an additional 38,292 shares during the quarter. Martingale Asset Management L P's holdings in Becton, Dickinson and Company were worth $17,082,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Smallwood Wealth Investment Management LLC acquired a new position in Becton, Dickinson and Company in the 1st quarter worth about $27,000. REAP Financial Group LLC increased its holdings in Becton, Dickinson and Company by 75.3% in the fourth quarter. REAP Financial Group LLC now owns 128 shares of the medical instruments supplier's stock worth $29,000 after buying an additional 55 shares during the last quarter. Alpine Bank Wealth Management bought a new position in Becton, Dickinson and Company during the first quarter valued at approximately $29,000. Cornerstone Planning Group LLC lifted its stake in Becton, Dickinson and Company by 341.4% in the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 99 shares during the last quarter. Finally, Nexus Investment Management ULC bought a new stake in Becton, Dickinson and Company in the first quarter worth approximately $34,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

BDX has been the subject of several analyst reports. Piper Sandler reaffirmed a "neutral" rating and issued a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research note on Friday, August 8th. William Blair lowered Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. The Goldman Sachs Group lowered Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $192.00 target price for the company. in a report on Friday, May 2nd. Barclays dropped their price target on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating on the stock in a research report on Tuesday, June 3rd. Finally, Bank of America downgraded shares of Becton, Dickinson and Company from a "buy" rating to a "neutral" rating and set a $190.00 price objective for the company. in a report on Thursday, May 1st. Four equities research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of "Hold" and an average target price of $211.44.

Becton, Dickinson and Company Stock Performance

BDX stock traded up $2.8730 on Friday, reaching $199.5030. 1,619,788 shares of the company were exchanged, compared to its average volume of 2,720,196. The firm has a market capitalization of $57.18 billion, a PE ratio of 35.88, a PEG ratio of 1.49 and a beta of 0.20. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The stock's fifty day moving average price is $180.65 and its 200 day moving average price is $195.26. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.28. The company had revenue of $5.51 billion for the quarter, compared to analyst estimates of $5.50 billion. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business's quarterly revenue was up 10.4% on a year-over-year basis. During the same period last year, the business posted $3.50 EPS. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th will be issued a $1.04 dividend. The ex-dividend date of this dividend is Monday, September 8th. This represents a $4.16 annualized dividend and a yield of 2.1%. Becton, Dickinson and Company's dividend payout ratio is 74.82%.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,185 shares of the stock in a transaction on Friday, July 18th. The shares were sold at an average price of $180.29, for a total value of $213,643.65. Following the completion of the transaction, the executive vice president owned 4,887 shares in the company, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP David Shan sold 1,166 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $171.19, for a total transaction of $199,607.54. Following the transaction, the executive vice president owned 4,575 shares of the company's stock, valued at approximately $783,194.25. This represents a 20.31% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,214 shares of company stock worth $579,206. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.